Drugs · acquisition-cost intelligence
Aller-chlor
chlorpheniramine maleate· ingredient chlorpheniramine· CHLORPHENIRAMINE MALEATE 4 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.01648
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other chlorpheniramine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Allergy Relief D | $0.05866 | +$0.04220 |
| ED A-HIST DM | $0.06685 | +$0.05040 |
| Coricidin HBP Cough and Cold | $0.10761 | +$0.09110 |
| Cold and Allergy | $0.22248 | +$0.20600 |
| ED-A-HIST DM | $0.42428 | +$0.40780 |
| Hydrocodone Polistirex and Chlorpheniramine Polistirex extended-release | $0.57986 | +$0.56340 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.